SP
$1.16
-0.03
(-2.52%)
As of Oct 5, 2026, 4:19 PM EDT
Price history
Spero Therapeutics (SPRO) is trading down at $1.16 (-2.52%), as of the latest quote. It operates in the Health Care sector.
IPO: November 2, 2017 · $14.00 offering · NASDAQ · View IPO details →
Spero Therapeutics revenue & net income history (FY2016–FY2025)
RevenueNet income
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $335.0K | $1.98M | $3.97M | $18.1M | $9.33M | $18.3M | $53.5M | $103.8M | $48.0M | $66.8M |
| Growth (year over year) | — | +490.7% | +100.4% | +357.6% | −48.6% | +95.7% | +193.1% | +94.0% | −53.8% | +39.2% |
| Operating income | −$33.2M | −$41.7M | −$42.8M | −$63.2M | −$79.1M | −$88.0M | −$42.2M | $21.5M | −$73.4M | $6.31M |
| Operating margin | −9916.7% | −2108.6% | −1079.3% | −348.4% | −847.9% | −481.9% | −78.9% | 20.7% | −152.9% | 9.5% |
| Net income | −$25.5M | −$38.7M | −$41.7M | −$60.9M | −$78.3M | −$89.8M | $46.4M | $22.8M | −$68.6M | $8.57M |
| Net margin | −7609.3% | −1957.7% | −1051.4% | −335.6% | −839.2% | −491.9% | 86.7% | 22.0% | −142.9% | 12.8% |
| EPS (diluted) | −$95.87 | −$17.82 | −$2.60 | −$3.35 | −$3.52 | −$2.91 | −$1.23 | $0.43 | −$1.27 | $0.15 |
| Balance sheet | ||||||||||
| Cash and equivalents | $10.3M | $87.3M | $34.1M | $29.7M | $85.2M | $112.6M | $109.1M | $76.3M | $52.9M | $40.3M |
| Total assets | $13.8M | $93.5M | $129.0M | $106.1M | $153.5M | $171.1M | $124.8M | $182.4M | $110.5M | $68.9M |
| Total liabilities | $7.41M | $8.52M | $13.2M | $31.5M | $21.4M | $82.8M | $48.9M | $75.5M | $64.4M | $9.90M |
| Shareholders' equity | −$45.4M | $84.6M | $115.5M | $74.6M | $132.0M | $88.3M | $75.9M | $106.9M | $46.1M | $59.0M |
| Cash flow | ||||||||||
| Operating cash flow | −$29.0M | −$39.1M | −$39.6M | −$50.0M | −$85.9M | −$64.3M | −$7.73M | −$33.0M | −$23.4M | −$12.6M |
| Capital expenditure | $830.0K | $27.0K | $2.44M | $314.0K | $157.0K | — | — | — | — | — |
| Free cash flow | −$29.8M | −$39.1M | −$42.1M | −$50.3M | −$86.0M | — | — | — | — | — |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $13.5M | $15.0M | $5.87M | $14.2M | $5.44M | — | $258.0K | $0 |
| Growth (year over year) | −47.1% | — | −36.6% | +39.1% | −59.6% | — | −95.6% | −100.0% |
| Operating income | −$18.6M | −$21.7M | −$14.7M | −$2.44M | −$7.92M | — | −$7.54M | −$9.93M |
| Operating margin | −138.0% | −144.4% | −250.8% | −17.2% | −145.5% | — | −2921.7% | — |
| Net income | −$17.1M | −$20.9M | −$13.9M | −$1.70M | −$7.38M | — | −$7.20M | −$9.55M |
| Net margin | −127.3% | −138.8% | −236.1% | −12.0% | −135.6% | — | −2791.9% | — |
| EPS (diluted) | −$0.32 | −$0.38 | −$0.25 | −$0.03 | −$0.13 | — | −$0.13 | −$0.16 |
| Balance sheet | ||||||||
| Cash and equivalents | $76.3M | $52.9M | $48.9M | $31.2M | $48.6M | $40.3M | $56.1M | $50.8M |
| Total assets | $135.2M | $110.5M | $77.7M | $62.1M | $54.2M | $68.9M | $59.0M | $52.8M |
| Total liabilities | $69.7M | $64.4M | $43.9M | $29.3M | $27.7M | $9.90M | $6.09M | $8.56M |
| Shareholders' equity | $65.5M | $46.1M | $33.8M | $32.8M | $26.5M | $59.0M | $52.9M | $44.2M |
| Cash flow | ||||||||
| Operating cash flow | $12.8M | −$23.4M | −$4.00M | −$17.7M | $17.4M | — | $15.9M | −$5.36M |
From Spero Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Spero Therapeutics
- Headquarters
- Cambridge, Massachusetts From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International